...which is just so pathetic. His personal, twisted vendetta against AMPE has gone so far that he posts on the Yahoo Message Board as Ampiooooh. "The Perp" is not a journalist, he is more like a propagandist of the worst sort.
Apiooooh/"The Perp" Fraudstein, why don't you crawl back into your hole and leave us alone. Most people on this Board have huge gains on their holdings, and look forward to the day AMPION is FDA approved. You are just a worm who spouts the same BS over & over again.
Well said. I despise the guy for his manipulative "journalism". That's why he's Adam "the Perp" Fraudstein.
...AMPE has always said that the current Optina trial MAY be sufficient for an NDA submission. "The Perp" attempts to twist this around to make it appear that AMPE is deceitful. If you bother to call the company, you will be told the same thing.
..with another misleading and grossly slanted article. It is incredible he is allowed to publish his rubbish attack articles regarding AMPE.
Why don't you move on to another Board. Nobody wants to hear about your technical BS. The vast majority of AMPE stockholders are investors who are holding in the belief that Ampion will achieve FDA approval. There are an endless amount of better stocks than AMPE to play small movements to the up & downside.
...the market cap is absurdly low for a Biotech with a likely blockbuster drug going commercial in late 2014 or 2015. And that doesn't assume any contribution from Optina, which could be big winner for AMPE. Look at similar Biotechs at this stage and you realize how undervalued AMPE is.
First off, almost all of these lawsuits are bogus and never amount to anything. Breach of fiduciary duty by the BOD?.....my only guess is maybe they've had offers from Big Pharma that they turned down. And they should - the stock is grossly undervalued when one considers the market potential of Ampion. Any opportunistic low ball bid by a potential acquirer should be spurned. Th market cap of AMPE currently is $300 million+. I feel that at a minimum it will be at $2 Billion+ sometime in 2015.
The head scratcher is why it's currently so cheap given the knockout recent trial results.
...amazing how he won't go away. I guess it's easy to be him, as most Biotechs eventually fail to some degree or another. But AMPE is a different story, and will prove to be one of Biotech's biggest winners.
..when Ampion is approved in 2014, the off-label usage will be hard to quantify, but could be HUGE. What's to stop a doctor for treating the many forms of tendonitis or various joint/hip ailments with an injection of Ampion vs cortizone/steroids?